SCHEMBL7989673

SCHEMBL7989673

O=C1c2ccccc2C(=O)N1CCCN1CCC(c2ccccc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.62
CHRM2 P08172 1/20 0.62
CHRM4 P08173 1/20 0.62
CHRM5 P08912 1/20 0.62
CHRM1 P11229 1/20 0.62
DRD2 P14416 1/20 0.62
CHRM3 P20309 1/20 0.62
DRD4 P21917 1/20 0.62
DRD3 P35462 1/20 0.62
SIGMAR1 Q99720 4/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HTR7 P34969 1/20 0.60
ALDH1A1 P00352 2/20 0.58
LMNA P02545 1/20 0.58
MAPT P10636 1/20 0.58
HPGD P15428 1/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
MEN1 O00255 1/20 0.57
TP53 P04637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5729537 0.97 HTR7 (0.63) HTR1ADRD2DRD3SIGMAR1SMN1; SMN2
SCHEMBL5658698 0.96 ALDH1A1 (0.63) HTR1ADRD2DRD3SIGMAR1SMN1; SMN2
SCHEMBL11806208 0.90 KDM4E (0.57) HTR1ACHRM2CHRM4CHRM5CHRM1
SCHEMBL6713388 0.89 DRD2 (0.55) HTR1ACHRM2CHRM4CHRM5CHRM1
SCHEMBL16406383 0.88 HTR7 (0.57) HTR1ACHRM2CHRM4CHRM5CHRM1
SCHEMBL11631627 0.87 DRD2 (0.57) HTR1ADRD2DRD3SIGMAR1HTR7
SCHEMBL11810138 0.86 HTR7 (0.59) HTR1ADRD2DRD3SIGMAR1HTR7
SCHEMBL11807263 0.86 HTR7 (0.59) HTR1ADRD2DRD3SIGMAR1HTR7
SCHEMBL7671816 0.84 DRD2 (0.79) HTR1ACHRM2CHRM4CHRM5CHRM1
SCHEMBL29459507 0.84 HTR1A (0.62) HTR1ADRD2DRD3HTR7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MARZABADI MOHAMMAD R 2007-02-22 US disclosed
US-6235731-B1 REDUCING BLOOD LIPIDS, SUGARS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed
EP-0915888-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS Takeda Chemical Industries, Ltd. (JP) 1999-05-19 EP disclosed
WO-1997040051-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MCHR1, MCHR2, MC1R HTR1A 29/4885CHRM2 274/4885CHRM4 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.